LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells
- DOI
- 10.1016/j.jpba.2024.116528
- Published
- 2025-01
- Container
- Journal of Pharmaceutical and Biomedical Analysis
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.jpba.2024.116528,
title = {LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells},
author = {Adam Hermawan and Anjar Windarsih and Dyaningtyas Dewi Pamungkas Putri and Nurul Fatimah},
year = {2025},
journal = {Journal of Pharmaceutical and Biomedical Analysis},
doi = {10.1016/j.jpba.2024.116528},
url = {https://doi.org/10.1016/j.jpba.2024.116528}
}RIS
TY - JOUR TI - LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells AU - Adam Hermawan AU - Anjar Windarsih AU - Dyaningtyas Dewi Pamungkas Putri AU - Nurul Fatimah PY - 2025 JO - Journal of Pharmaceutical and Biomedical Analysis DO - 10.1016/j.jpba.2024.116528 UR - https://doi.org/10.1016/j.jpba.2024.116528 ER -
APA
Hermawan, A., Windarsih, A., Putri, D. D. P., & Fatimah, N. (2025). LC-HRMS-based global metabolomics profiling unravels the distinct metabolic signature of lapatinib-resistant and trastuzumab-resistant HER2+ breast cancer cells. Journal of Pharmaceutical and Biomedical Analysis. https://doi.org/10.1016/j.jpba.2024.116528
Source records
- crossref · retrieved 2026-09-27T10:03:05.501Z